153 related articles for article (PubMed ID: 7568175)
21. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
Zhu DM; Uckun FM
Clin Cancer Res; 2000 Jun; 6(6):2456-63. PubMed ID: 10873099
[TBL] [Abstract][Full Text] [Related]
22. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.
Herrera L; Stanciu-Herrera C; Morgan C; Ghetie V; Vitetta ES
Leuk Lymphoma; 2006 Nov; 47(11):2380-7. PubMed ID: 17107913
[TBL] [Abstract][Full Text] [Related]
24. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
25. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification.
Fujimoto M; Fujimoto Y; Poe JC; Jansen PJ; Lowell CA; DeFranco AL; Tedder TF
Immunity; 2000 Jul; 13(1):47-57. PubMed ID: 10933394
[TBL] [Abstract][Full Text] [Related]
26. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
Messinger Y; Reaman GH; Ek O; Uckun FM
Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
[TBL] [Abstract][Full Text] [Related]
28. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
[TBL] [Abstract][Full Text] [Related]
29. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
30. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
Uckun FM; Qazi S; Dibirdik I; Myers DE
Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
[TBL] [Abstract][Full Text] [Related]
31. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
32. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Yang P; Dong F; Zhou Q
Toxicol Lett; 2017 Aug; 278():9-17. PubMed ID: 28666825
[TBL] [Abstract][Full Text] [Related]
33. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.
Scheuermann RH; Racila E
Leuk Lymphoma; 1995 Aug; 18(5-6):385-97. PubMed ID: 8528044
[TBL] [Abstract][Full Text] [Related]
34. Eradication of CD19+ leukemia by targeted calicheamicin θ.
Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
[TBL] [Abstract][Full Text] [Related]
35. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Buhl AM; Cambier JC
J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.
Tsai LK; Pop LM; Liu X; Vitetta ES
Toxins (Basel); 2011 Apr; 3(4):409-19. PubMed ID: 22069716
[TBL] [Abstract][Full Text] [Related]
38. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
[TBL] [Abstract][Full Text] [Related]
39. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH
Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978
[TBL] [Abstract][Full Text] [Related]
40. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
